Gardasil

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

87 competitors in Immunogenicity

#DrugCompanyPhaseTrials

1

Perjeta

Roche

Phase 3

22

Rabies Vaccine

Novartis

Phase 3

123

Prolia

OOrganon and Co

Phase 3

24

HPV Vaccine

SShanghai Zerun Biotechnology Co.,Ltd

Phase 3

35

Gardasil-9

BBeijing Health Guard Biotechnology, Inc

Phase 3

26

Rsvpref

Pfizer

Phase 3

57

Bexsero

GSK

Phase 3

88

PCV21

Sanofi

Phase 3

19

Opfolda

Johnson & Johnson

Phase 3

110

Pentavalent Vaccine

GSK

Phase 3

1Show 29 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Papilloma11 trials

Pilot Study to Determine the Safety and Efficacy of Gardasil Against the Human Papilloma Virus (HPV) in HIV-infected Men

Unknown status·SSouthern California Institute for Research and Education·N/A·NCT00666107·150 enrolled

Human Papillomavirus Screening and Vaccine Readiness Program

Withdrawn·PPublic Health Research Institute, India··NCT00863096·450 enrolled

Acceptability of Human Papillomavirus (HPV) Vaccine in Female Sex Workers

Completed·JJohns Hopkins Bloomberg School of Public Health·Phase 4·NCT00925288·200 enrolled

Show 8 more trials

Phase 3 Trial of a Bivalent Human Papilloma Virus (HPV) Vaccine (Cecolin®) in Young Girls

Completed·PPATH·Phase 3·NCT04508309·1,025 enrolled

A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00798265·26 enrolled

Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)

Active, not recruiting·Merck & Co.··NCT02653118·4,453 enrolled

Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED)

Completed·Merck & Co.·Phase 3·NCT00157950·176 enrolled

Immune Response to Bivalent and Tetravalent Human Papillomavirus Vaccine in HIV Infected Adults

Completed·UUniversity of Aarhus·Phase 4·NCT01386164·92 enrolled

Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age

Completed·GSK·Phase 3·NCT00423046·1,106 enrolled

Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China

Unknown status·CChinese Academy of Medical Sciences·Phase 4·NCT01021904·6,200 enrolled

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females

Completed·GSK·Phase 3·NCT01462357·1,079 enrolled

Immunogenicity7 trials

Immunogenicity and Safety Study of NBP615 in Healthy Female

Completed·SSK Bioscience Co., Ltd.·Phase 1/2·NCT04453241·200 enrolled

Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Recruiting·SShanghai Bovax Biotechnology Co., Ltd.·Phase 3·NCT04422366·8,000 enrolled

Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Completed·SShanghai Bovax Biotechnology Co., Ltd.·Phase 3·NCT04425291·1,680 enrolled

Show 4 more trials

Immunogenicity and Tolerability of V503 Versus GARDASIL (V503-009)

Completed·Merck & Co.·Phase 3·NCT01304498·600 enrolled

Immunogenicity and Safety of HPV Vaccine Gardasil in Young Women

Completed·UUniversity of Chicago·N/A·NCT00786409·27 enrolled

A Phase I Safty and Immunogenicity Study of SCT1000 in Healthy Women Aged 18 to 45 Years

Unknown status·SSinocelltech Ltd.·Phase 1·NCT04921111·240 enrolled

Safety and Immunogenicity of HPV Vaccine Administered Intradermally and Intramuscularly Via Needle-Free Injection System

Withdrawn·PPharmaJet, Inc.·Phase 2·NCT06142461

Cervical Cancer2 trials

A Model for Implementation of Cervical Cancer Screening and HPV Vaccination the Emergency Department: a Pilot Study

Unknown status·—·N/A·NCT01133509·100 enrolled

FASTER-Tlalpan Study in Mexico: HPV Vaccination Impact on Cervical Cancer Screening Program

Completed·IInstituto Nacional de Salud Publica, Mexico·Phase 4·NCT03105856·3,000 enrolled

Intraepithelial Neoplasia1 trial

HPV (Human Papilloma Virus) Vaccination After Treatment of Anal Intraepithelial Neoplasia (AIN)

Completed·—·Phase 4·NCT02087384·126 enrolled

Phase II1 trial

A Phase II Study of SCT1000 in Healthy Women Aged 18 to 45 Years

Unknown status·SSinocelltech Ltd.·Phase 2·NCT05060484·1,800 enrolled

13 more indications

Clinical Trial1 trial

A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17

Completed·Pfizer·Phase 2·NCT01461993·2,499 enrolled

Adolescent1 trial

Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls

Completed·PPublic Health England·Phase 4·NCT00956553·400 enrolled

Child1 trial

The Development of a "Mother/Child, Screen, Treat and Vaccinate Program" in Manchay and Iquitos, Peru

Completed·PPreventive Oncology International, Inc.·Phase 1·NCT01338051·642 enrolled

Stem Cell Transplant Patients1 trial

Gardasil Vaccination in Post Stem Cell Transplant Patients

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 1·NCT01092195·64 enrolled

Immune Response1 trial

A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020)

Completed·Merck & Co.·Phase 3·NCT02114385·500 enrolled

Cohort Study1 trial

The Prospective Cohort Study to Evaluate the Preventive Efficacy of HPV Vaccine in Japanese Women Aged 27-45 Years

Unknown status·—··NCT04022148·2,800 enrolled

Adult1 trial

Study of Gardasil in Mid-Adult Males (MAM)

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT01432574·150 enrolled

Vaccine1 trial

Study to Determine if Gardasil Vaccine is Safe and Effective in Lupus Patients

Completed·WWayne State University·Phase 1·NCT01741012·37 enrolled

HPV Vaccine1 trial

Study of the Molecular Mechanisms Underlying the Cross-neutralizing Capacity of AS04-adjuvanted HPV Vaccine (Cervarix®) in Comparison With the Aluminiumhydroxyphosphate Sulphate Adjuvanted HPV Vaccine (Gardasil®)

Completed·UUniversity Hospital, Ghent·Phase 4·NCT01914367·12 enrolled

Prevention1 trial

Prevention and Control of Neoplasms Associated With HPV in High-risk Groups in Mexico City: The Condesa Study

Completed·IInstituto Nacional de Salud Publica, Mexico·Phase 2/3·NCT05149248·6,000 enrolled

HIV-1 infection1 trial

Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection

Completed·AAIDS Malignancy Consortium·Phase 2·NCT00513526·112 enrolled

Idiopathic CD4 T Cell Lymphocytopenia1 trial

A Phase 2, Open-Label Study to Assess the Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in Patients With Idiopathic CD4 T Cell Lymphocytopenia

Active, not recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT03519464·54 enrolled

Papillomavirus Infections1 trial

A Phase 3 Randomized, Double-Blinded, Controlled With GARDASIL® Efficacy, Immunogenicity and Safety Study of V503 [a 9-Valent HPV Vaccine] in Chinese Women 20 to 45 Years of Age

Active, not recruiting·Merck & Co.·Phase 3·NCT03998254·6,000 enrolled

Details

Drug Info

Related News